Last updated: 2026-09-06 20:49:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Nexalin Technology, Inc. (NXL) operates in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $5.03, with a market capitalisation of $5.13M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.80 to $60.00. This page covers its latest market performance, valuation, price trends and company information.
$5.13M | |
$5.36 | |
$1,016.40 | |
$4.80 | |
$5.36 | |
13.33K | |
-- | |
-- | |
$60.00 | |
$4.80 | |
-- | |
-- |
Nexalin Technology, Inc. (NXL) last closed at $5.36 as of 2026-09-04 23:56:00, unchanged from the previous close of $5.36.
During the latest regular trading session, NXL traded between $4.80 and $1,016.40, with a volume of 13.33K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Nexalin Technology, Inc. (NXL) moved from $6.28 to $5.03, representing a decline of 19.98% ($1.26).
The stock traded between $4.80 and $5.84 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 23.95 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.4%
NXL is currently trading at $5.03, placing it 0.4% of the way from its 52-week low of $4.80 to its 52-week high of $60.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
| Industry | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Nexalin Technology, Inc. (NXL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.